The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
Eligible age
18–120 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The most common types of acute leukaemia are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cells and the most common and severe malignant leukemia in adults and is responsible for the highest mortality from leukemia. ALL is a neoplasm characterized by the growth of malignant lymphoblasts of the B or T lineage, leading to an inhibition of proliferation of the normal blood cell lineages. The primary objectives of this study are investigating the safety, tolerability, and the MTD of LBS-007. The secondary objectives are to assess the efficacy and to determine the pharmacokinetics (PK) of LBS-007. The exploratory objective is to study and correlate the changes in surrogate biomarkers in response to treatment.
Sponsor: Lin BioScience, Inc
You may qualify if…
- ✓ Male or female subjects greater than 18 years old, inclusive.
- ✓ Pathologically confirmed diagnoses of Relapsed or resistant AML or ALL.
- ✓ Patients who are ineligible for standard therapies that are anticipated to result in durable remission or cure, or who have no known therapy options of documented benefit.
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
You may not qualify if…
- ✕ Concomitant chemotherapy, radiation therapy, or immunotherapy.
- ✕ Receiving any other investigational agents concurrently or within 30 days prior to screening.
- ✕ Patient has acute promyelocytic leukaemia or leukemia with active CNS involvement.
- ✕ History of another active malignancy with 2 years prior to study entry, basal cell skin cancer and previous carcinoma in treated curatively.
- ✕ Patient with mental deficits and/or psychiatric history that precludes them from giving informed consent or from following protocol.
Where it's recruiting
Tampa
Chicago
Fairway
Baltimore
Chapel Hill
Nedlands · Perth
Source: ClinicalTrials.gov · NCT05756322 · last updated 2026-03-27